Share price movements
On January 25, Bristol-Myers Squibb (BMY) closed at $48.93, which is 0.18% lower than its previous closing price. The company closed at a premium of 10.45% compared to its 52-week low price of $44.30. Bristol-Myers Squibb closed at a discount of 30.15% compared to its 52-week high price of $70.05. At end of January 25, Bristol-Myers Squibb’s market capitalization was $80.01 billion. The company is trading at a trailing PE ratio of 16.00x and a forward PE ratio of 11.08x.
Based on the closing price on January 25, Bristol-Myers Squibb reported returns of -1.35% in the last week, 0.35% in the last month, and -3.40% in the last quarter. Bristol-Myers Squibb also reported returns of -17.12% in the last half year, -23.26% in the last year, and -5.87% YTD.
Based on the closing price on January 25, the broader healthcare sector, represented by Health Care Select Sector SPDR ETF (XLV), reported returns of -0.11% in the last week, 10.19% in the last month, and -1.50% in the last quarter. IBB also reported returns of 0.08% in the last half year, 0.08% in the last year, and 2.79% YTD (year-to-date).
Bristol-Myers Squibb has significantly underperformed XLV in 2019 YTD.
Analysts’ recommendations and target prices
Among the 14 analysts covering Bristol-Myers Squibb on January 27, four recommended a “strong buy,” two recommended a “buy,” and eight recommended a “hold.”
Analysts’ 12-month consensus recommendation for Bristol-Myers Squibb on January 27 is a “buy.” The company’s 12-month consensus target price is $56.75, which is 15.98% higher than its closing price on January 25. The highest, median, and lowest target price estimates for the company are $63, $56, and $52, respectively.
Next, we’ll discuss Bristol-Myers Squibb’s revenue expectations for fiscal 2019.